Key facts
- Affinia Therapeutics’s last known valuation is $145.0M (Oct 2025).
- It has raised $210.0M across 3 recorded rounds; the latest was Early Stage VC ($13.3M) in Sep 2025.
- Notable investors include RA Capital Management, GV, Service Provider Capital, New Enterprise Associates, F-Prime Capital — 19 tracked in total.
- Affinia Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently May 2021 ($110.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Affinia Therapeutics
Funding rounds
3 roundsAbout Affinia Therapeutics
Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2019
- Employees
- 51
- Website
- affiniatx.com/
- Ownership
- Privately Held (backing)
Affinia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Affinia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Affinia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.